Growth Metrics

Axsome Therapeutics (AXSM) Other Non-Current Liabilities: 2022-2025

Historic Other Non-Current Liabilities for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $89.9 million.

  • Axsome Therapeutics' Other Non-Current Liabilities rose 8.30% to $89.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.9 million, marking a year-over-year increase of 8.30%. This contributed to the annual value of $91.7 million for FY2024, which is 25.08% up from last year.
  • Per Axsome Therapeutics' latest filing, its Other Non-Current Liabilities stood at $89.9 million for Q3 2025, which was up 12.82% from $79.7 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Other Non-Current Liabilities ranged from a high of $91.7 million in Q4 2024 and a low of $27.4 million during Q3 2022.
  • In the last 3 years, Axsome Therapeutics' Other Non-Current Liabilities had a median value of $73.3 million in 2023 and averaged $67.4 million.
  • Data for Axsome Therapeutics' Other Non-Current Liabilities shows a peak YoY surged of 163.01% (in 2024) over the last 5 years.
  • Over the past 4 years, Axsome Therapeutics' Other Non-Current Liabilities (Quarterly) stood at $31.1 million in 2022, then soared by 135.69% to $73.3 million in 2023, then rose by 25.08% to $91.7 million in 2024, then rose by 8.30% to $89.9 million in 2025.
  • Its Other Non-Current Liabilities stands at $89.9 million for Q3 2025, versus $79.7 million for Q2 2025 and $90.6 million for Q1 2025.